$ABT
Abbott Laboratories · NYSE · Healthcare
- Market cap
- 187.45B
- Volume
- 6.88M
- P/E
- 35.06
- Day range
- 107.36 – 110.01
- 52w range
- 81.97 – 137.49
- Analyst target
- 120.20
AI Summary
Generating a unique summary for ABT…
AI-generated for information only — not investment advice.
Share this ticker
$ABT -0.42% at 108.33 David Tepper and 1 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/ABT
Company summary
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Institutional ownership
Institutions hold 81.91% · insiders 0.50% · 3,810 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 152.56M | $16.53B | 8.82% | 2026-06-30 |
| Vanguard Capital Management LLC | 113.75M | $12.32B | 6.57% | 2026-06-30 |
| State Street Corporation | 80.93M | $8.77B | 4.68% | 2026-06-30 |
| Charles Schwab Investment Management, Inc. | 59.67M | $6.46B | 3.45% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 49.02M | $5.31B | 2.83% | 2026-06-30 |
| Geode Capital Management, LLC | 39.22M | $4.25B | 2.27% | 2026-06-30 |
| Capital Research Global Investors | 36.91M | $4.00B | 2.13% | 2026-06-30 |
| Capital International Investors | 34.65M | $3.75B | 2.00% | 2026-06-30 |
| Morgan Stanley | 26.61M | $2.88B | 1.54% | 2026-06-30 |
| NORGES BANK | 23.35M | $2.53B | 1.35% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| MCCOY JOHN A. JR | Officer | Sale at price 109.54 per share. | 27.00 | 2026-09-02 |
| FORD ROBERT B. | Chief Executive Officer | Conversion of Exercise of derivative security at price 44.40 - 59.94 per share. | 398.8K | 2026-08-25 |
| FORD ROBERT B. | Chief Executive Officer | Sale at price 115.57 - 116.19 per share. | 398.8K | 2026-08-25 |
| MORRONE LOUIS H | Officer | Sale at price 109.83 per share. | 5.8K | 2026-08-11 |
| STRATTON JOHN G. | Director | Purchase at price 86.82 per share. | 2.0K | 2026-05-07 |
| STARKS DANIEL J | Director | Purchase at price 92.65 per share. | 10.0K | 2026-04-27 |
| ROMAN MICHAEL F | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
| KUMBIER MICHELLE A | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
| BLOUNT SALLY E | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
| CONROY KEVIN T | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
| MCKINSTRY NANCY | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
| STRATTON JOHN G. | Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | 2026-04-24 |
Analyst ratings
Consensus score 1.59 (1 = strong buy, 5 = sell) · mean target 120.20
- TD CowenBuymain2026-08-25
- TD CowenBuymain2026-08-21
- CitigroupBuymain2026-08-14
- Wolfe ResearchOutperformup2026-08-13
- UBSBuymain2026-07-28
- CitigroupBuymain2026-07-17
- Piper SandlerOverweightreit2026-07-17
- JP MorganOverweightmain2026-07-17
- Wells FargoOverweightmain2026-07-17
- TD CowenBuyreit2026-07-17
Earnings
Next report: 2026-10-14
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 1.30 | 1.30 | 0.00 |
| 4Q2025 | 1.50 | 1.49 | 0.01 |
| 1Q2026 | 1.15 | 1.15 | 0.00 |
| 2Q2026 | 1.31 | 1.28 | 0.03 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-08-20Open
- 10-QPeriodic Financial Reports2026-07-28Open
- 8-KCorporate Changes & Voting Matters2026-07-16Open
- 11-KAnnual report of employee stock purchase2026-06-18Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-27Open
- 10-QPeriodic Financial Reports2026-04-29Open
- 8-KCorporate Changes & Voting Matters2026-04-27Open
- S-8Offering Registrations2026-04-24Open
- 8-KCorporate Changes & Voting Matters2026-04-17Open
- 8-KCorporate Changes & Voting Matters2026-04-16Open
Latest ABT news
- Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery
Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.
Mon, 07 Sep 2026 08:21:00 +0000
- Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Sun, 06 Sep 2026 12:50:00 +0000
- How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Fri, 04 Sep 2026 18:25:39 +0000
- Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
Thu, 03 Sep 2026 12:54:00 +0000
- Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.
Wed, 02 Sep 2026 21:50:01 +0000
- The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.
Wed, 02 Sep 2026 17:52:36 +0000
- Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the "SRC")
Wed, 02 Sep 2026 15:45:00 +0000
- 3 Reasons to Sell PACB and 1 Stock to Buy Instead
Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Wed, 02 Sep 2026 15:32:23 +0000